Tetrahydrobiopterin improves endothelial function in cardiovascular disease: A systematic review

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  Wang, Qiongying ^a   Yang, Mina ^a   Xu, Han ^a   Yu, Jing ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PLACEBO; TETRAHYDROBIOPTERIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COCHRANE LIBRARY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DATA BASE; DIABETIC ANGIOPATHY; DISEASE COURSE; EMBASE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MEDLINE; OUTCOME ASSESSMENT; PULMONARY HYPERTENSION; REVIEW; SKIN BLOOD FLOW; SYSTEMATIC REVIEW; VASODILATATION;

EID: 84919474441     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/850312     Document Type: Review

References (44)

1. A. S. Go, D. Mozaffarian, V. L. Roger et al., "Heart disease and stroke statistics-2013 update: a report from the american heart association," Circulation, vol. 127, no. 1, pp. e6-e245, 2013.
2. H. Cai and D. G. Harrison, "Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress," Circulation Research, vol. 87, no. 10, pp. 840-844, 2000.
3. T. Heitzer, T. Schlinzig, K. Krohn, T. Meinertz, and T. Münzel, "Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease," Circulation, vol. 104, no. 22, pp. 2673-2678, 2001.
4. A. A. Quyyumi, "Prognostic value of endothelial function," The American Journal of Cardiology, vol. 91, no. 12, pp. 19-24, 2003.
5. B. Healy, "Endothelial cell dysfunction: an emerging endocrinopathy linked to coronary disease," Journal of the American College of Cardiology, vol. 16, no. 2, pp. 357-358, 1990.
6. J. P. J. Halcox, W. H. Schenke, G. Zalos et al., "Prognostic value of coronary vascular endothelial dysfunction," Circulation, vol. 106, no. 6, pp. 653-658, 2002.
7. R. Fathi, B. Haluska, N. Isbel, L. Short, and T. H. Marwick, "The relative importance of vascular structure and function in predicting cardiovascular events," Journal of the American College of Cardiology, vol. 43, no. 4, pp. 616-623, 2004.
8. E. R. Werner, N. Blau, and B. Thöny, "Tetrahydrobiopterin: biochemistry and pathophysiology," Biochemical Journal, vol. 438, no. 3, pp. 397-414, 2011.
9. M. A. Tayeh and M. A. Marletta, "Macrophage oxidation of Larginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor," Journal of Biological Chemistry, vol. 264, no. 33, pp. 19654-19658, 1989.
10. N. S. Kwon, C. F. Nathan, and D. J. Stuehr, "Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages," The Journal of Biological Chemistry, vol. 264, no. 34, pp. 20496-20501, 1989.
11. J. M. Hill, G. Zalos, J. P. J. Halcox et al., "Circulating endothelial progenitor cells, vascular function, and cardiovascular risk," The New England Journal of Medicine, vol. 348, no. 7, pp. 593-600, 2003.
12. M. Porkert, S. Sher, U. Reddy et al., "Tetrahydrobiopterin: a novel antihypertensive therapy," Journal of Human Hypertension, vol. 22, no. 6, pp. 401-407, 2008.
13. W. Maier, F. Cosentino, R. B. Lütolf et al., "Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease," Journal of Cardiovascular Pharmacology, vol. 35, no. 2, pp. 173-178, 2000.
14. F. Cosentino, D. Hürlimann, C. Delli Gatti et al., "Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia," Heart, vol. 94, no. 4, pp. 487-492, 2008.
15. T. Heitzer, K. Krohn, S. Albers, and T. Meinertz, "Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus," Diabetologia, vol. 43, no. 11, pp. 1435-1438, 2000.
16. I. M. Robbins, A. R. Hemnes, J. S. Gibbs et al., "Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension," Experimental Lung Research, vol. 37, no. 1, pp. 26-34, 2011.
17. T. Heitzer, C. Brockhoff, B. Mayer et al., "Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase," Circulation Research, vol. 86, no. 2, pp. e36-e41, 2000.
18. S. Ueda, H. Matsuoka, H. Miyazaki, M. Usui, S. Okuda, and T. Imaizumi, "Tetrahydrobiopterin restores endothelial function in long-term smokers," Journal of the American College of Cardiology, vol. 35, no. 1, pp. 71-75, 2000.
19. J. A. Lang, L. A. Holowatz, and W. L. Kenney, "Localized tyrosine or tetrahydrobiopterin supplementation corrects the age-related decline in cutaneous vasoconstriction," The Journal of Physiology, vol. 588, no. 8, pp. 1361-1368, 2010.
20. A. E. Stanhewicz, R. S. Bruning, C. J. Smith, W. L. Kenney, and L. A. Holowatz, "Local tetrahydrobiopterin administration augments reflex cutaneous vasodilation through nitric oxide-dependent mechanisms in aged human skin," Journal of Applied Physiology, vol. 112, no. 5, pp. 791-797, 2012.
21. G. L. Pierce, K. L. Jablonski, A. E. Walker et al., "Tetrahydrobiopterin supplementation enhances carotid artery compliance in healthy older men: a pilot study," American Journal of Hypertension, vol. 25, no. 10, pp. 1050-1054, 2012.
22. S. Setoguchi, M. Mohri, H. Shimokawa, and A. Takeshita, "Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease," Journal of the American College of Cardiology, vol. 38, no. 2, pp. 493-498, 2001.
23. T. Nyström, A. Nygren, and A˚. Sjöholm, "Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease," TheAmerican Journal of Physiology, vol. 287, no. 5, pp. E919-E925, 2004.
24. M. I.Worthley, R. S. Kanani, Y.-H. Sun et al., "Effects of tetrahydrobiopterin on coronary vascular reactivity in atherosclerotic human coronary arteries," Cardiovascular Research, vol. 76, no. 3, pp. 539-546, 2007.
25. M. Settergren, F. Böhm, R. E. Malmström, K. M. Channon, and J. Pernow, "l-Arginine and tetrahydrobiopterin protects against ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease," Atherosclerosis, vol. 204, no. 1, pp. 73-78, 2009.
26. C. Cunnington, T. Van Assche, C. Shirodaria et al., "Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease," Circulation, vol. 125, no. 11, pp. 1356-1366, 2012.
27. E. Stroes, J. Kastelein, F. Cosentino et al., "Tetrahydrobiopterin restores endothelial function in hypercholesterolemia," The Journal of Clinical Investigation, vol. 99, no. 1, pp. 41-46, 1997.
28. C. A. Wyss, P. Koepfli, M. Namdar et al., "Tetrahydrobiopterin restores impaired coronary microvascular dysfunction in hypercholesterolaemia," European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 1, pp. 84-91, 2005.
29. L. A. Holowatz and W. L. Kenney, "Acute localized administration of tetrahydrobiopterin and chronic systemic atorvastatin treatment restore cutaneous microvascular function in hypercholesterolaemic humans," The Journal of Physiology, vol. 589, no. 19, pp. 4787-4797, 2011.
30. Y. Fukuda, H. Teragawa, K. Matsuda, T. Yamagata, H. Matsuura, and K. Chayama, "Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia," Heart, vol. 87, no. 3, pp. 264-269, 2002.
31. Y. Higashi, S. Sasaki, K. Nakagawa et al., "Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals," The American Journal of Hypertension, vol. 15, no. 4, pp. 326-332, 2002.
32. N. Ihlemann, C. Rask-Madsen, A. Perner et al., "Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects," American Journal of Physiology: Heart and Circulatory Physiology, vol. 285, no. 2, pp. H875-H882, 2003.
33. J. Yan, G. Tie, and L. M. Messina, "Tetrahydrobiopterin, Larginine and vitamin C act synergistically to decrease oxidant stress and increase nitric oxide that increases blood flow recovery after hindlimb ischemia in the rat," Molecular Medicine, vol. 18, no. 8, pp. 1221-1230, 2012.
34. K. L. Moreau, A. Meditz, K. D. Deane, and W. M. Kohrt, "Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women," American Journal of Physiology-Heart and Circulatory Physiology, vol. 302, no. 5, pp. H1211-H1218, 2012.
35. M. J. Crabtree, C. L. Smith, G. Lam, M. S. Goligorsky, and S. S. Gross, "Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucoseelicited changes in NO vs. superoxide production by eNOS," American Journal of Physiology: Heart and Circulatory Physiology, vol. 294, no. 4, pp. H1530-H1540, 2008.
36. M. J. Crabtree, A. L. Tatham, Y. Al-Wakeel et al., "Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status insights from cells with TET-regulated GTP cyclohydrolasei expression," Journal of Biological Chemistry, vol. 284, no. 2, pp. 1136-1144, 2009.
37. L. V. d'Uscio, S. Milstien, D. Richardson, L. Smith, and Z. S. Katusic, "Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity," Circulation Research, vol. 92, no. 1, pp. 88-95, 2003.
38. P. Pacher, J. S. Beckman, and L. Liaudet, "Nitric oxide and peroxynitrite in health and disease," Physiological Reviews, vol. 87, no. 1, pp. 315-424, 2007.
39. R. Heller, A. Unbehaun, B. Schellenberg, B. Mayer, G. Werner-Felmayer, and E. R. Werner, " l-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin," The Journal of Biological Chemistry, vol. 276, no. 1, pp. 40-47, 2001.
40. A. Huang, J.A. Vita, R. C. Venema, and J. F. Keaney Jr., "Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin," The Journal of Biological Chemistry, vol. 275, no. 23, pp. 17399-17406, 2000.
41. A. Mortensen, S. Hasselholt, P. Tveden-Nyborg, and J. Lykkesfeldt, "Guinea pig ascorbate status predicts tetrahydrobiopterin plasma concentration and oxidation ratio in vivo," Nutrition Research, vol. 33, no. 10, pp. 859-867, 2013.
42. K. Sawabe, Y. Suetake, N. Nakanishi, K. O. Wakasugi, and H. Hasegawa, "Cellular accumulation of tetrahydrobiopterin following its administration is mediated by two different processes; direct uptake and indirect uptake mediated by a methotrexatesensitive process," Molecular Genetics and Metabolism, vol. 86, pp. 133-138, 2005.
43. C. Antoniades, C. Shirodaria, M. Crabtree et al., "Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation," Circulation, vol. 116, no. 24, pp. 2851-2859, 2007.
44. J. Whitsett, A. R. Filho, S. Sethumadhavan, J. Celinska, M. Widlansky, and J. Vasquez-Vivar, "Human endothelial dihydrofolate reductase low activity limits vascular tetrahydrobiopterin recycling," Free Radical Biology and Medicine, vol. 63, pp. 143-150, 2013.